Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M192,591Revenue (TTM) $M49,778Net Margin (%)13.6Altman Z-Score2.6
Enterprise Value $M219,547EPS (TTM) $2.8Operating Margin %17.0Piotroski F-Score5
P/E(ttm)28.6Beneish M-Score-2.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %1.4Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-2.1Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow22.0y-y EBITDA Growth Rate %-16.8ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.4PEG--ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %98.0Shares Outstanding M2,381ROIC % (ttm)7.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2016-06-30 Reduce-0.05%$71.4 - $82.51
($77.03)
$ 80.885%Reduce -1.53%44,366,511
NVSTweedy Browne 2016-06-30 Reduce-0.01%$71.4 - $82.51
($77.03)
$ 80.885%Reduce -1.63%233,783
NVSKen Fisher 2016-06-30 Add0.01%$71.4 - $82.51
($77.03)
$ 80.885%Add 1.22%6,363,641
NVSMario Gabelli 2016-06-30 Reduce$71.4 - $82.51
($77.03)
$ 80.885%Reduce -12.38%6,015
NVSJohn Rogers 2016-06-30 Add$71.4 - $82.51
($77.03)
$ 80.885%Add 11.45%14,818
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 80.886%Add 1.59%6,287,099
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 80.886%New holding3,700
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 80.886%Reduce -1.87%237,664
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 80.886%Add 18.01%13,296
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 80.886%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 80.886%Reduce -0.12%45,054,916
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 80.88-9%Reduce -1.35%45,107,085
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 80.88-9%Reduce -3.15%27,643
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 80.88-9%Reduce -2.74%242,201
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 80.88-9%Add 0.92%6,188,893
NVSJohn Rogers 2015-12-31 Buy 0.01%$83.96 - $95.03
($88.53)
$ 80.88-9%New holding11,267
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 80.88-9%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 80.88-19%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 80.88-19%Add 1.28%6,132,211
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 80.88-19%Reduce -2.04%249,022
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15439.2view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    A Double Dose of Trouble at Novartis Sep 22 2016 
    Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Pharmaceuticals are the New Bonds Aug 30 2016 
    Merck Offers Value and Steady Dividend Growth Aug 24 2016 
    Novartis: First-Class Pharmaceuticals Aug 19 2016 
    Novartis Needs to Stem the Bleeding From Gleevec Decline Aug 16 2016 
    GlaxoSmithKline's Dividend Health Aug 09 2016 
    Can Novartis Win the Entresto Bet? Aug 03 2016 
    Tweedy Browne 2nd Quarter Shareholder Letter Aug 01 2016 

    More From Other Websites
    Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval Sep 27 2016
    Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19 Sep 27 2016
    ETF’s with exposure to Novartis AG : September 26, 2016 Sep 26 2016
    The Internet of Medical Things: 6 Stocks in Focus Sep 26 2016
    Novartis Ilaris Approved for Extended Use in Periodic Fever Sep 26 2016
    3:21 am Novartis reports positive top-line results from ASCEND-4; moving forward with global... Sep 25 2016
    Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare... Sep 23 2016
    Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic... Sep 23 2016
    Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study Sep 23 2016
    UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure Sep 23 2016
    Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in... Sep 23 2016
    Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle Sep 22 2016
    A Double Dose of Trouble at Novartis Sep 22 2016
    Does Novartis AG (NVS) Have The Solution For Malaria? Sep 22 2016
    Novel Novartis malaria compound shows potential to be effective against infections resistant to all... Sep 21 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)